Journals / The Journal of Pediatric Research / 2019 / Cilt: 6 - Sayı: 1

Do We Have to Obtain Rebound Bilirubin Levels and What is the Optimal Time?

Pages
7–11
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Randomized controlled studies with larger sample sizes are still needed for definitive recommendations.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: We aimed to determine the frequency of rebound hyperbilirubinemia (RHB) needing treatment and therefrom, to clarify the clinical importance of routinely checking serum total bilirubin (STB) levels after the cessation of phototherapy and to define an optimal time to check STB levels for the detection of RHB.Materials and Methods: Term and late preterm babies who received phototherapy were included in this study.
📊
Key Findings & Data:Serum “rebound” bilirubin measurements were performed two times at 12 and at 24 hours after the cessation of phototherapy.
💡
Conclusion & Impact:Randomized controlled studies with larger sample sizes are still needed for definitive recommendations.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

Aim: We aimed to determine the frequency of rebound hyperbilirubinemia (RHB) needing treatment and therefrom, to clarify the clinical importance of routinely checking serum total bilirubin (STB) levels after the cessation of phototherapy and to define an optimal time to check STB levels for the detection of RHB.Materials and Methods: Term and late preterm babies who received phototherapy were included in this study. The demographic and clinical features, time of onset of jaundice, phototherapy time and results to determine the etiology of jaundice were recorded for all babies. Serum “rebound” bilirubin measurements were performed two times at 12 and at 24 hours after the cessation of phototherapy. The re-initiation of phototherapy according to the 12th and 24th hour STB levels was accepted as “early rebound” and “late rebound”, respectively. IBM SPSS 22 was used for statistical analyses.Results: Data was available for 110 infants. The rebound rate requiring phototherapy was 9.1% (n=10) and all had a risk factor. Most of the babies (9/10) rebounded at the 12th hour after the termination of phototherapy. Hemolysis and prematurity were found to be statistically significant for RHB (p=0.008; p=0.048).Conclusion: Post-phototherapy bilirubin follow-up may be incorporated using a combined approach of individualization, evaluation of risk factors, and application of common sense before discharge. Our study showed that STB levels could be measured after the cessation of phototherapy, especially in patients with a risk factor, at the 12th hour before discharge. Randomized controlled studies with larger sample sizes are still needed for definitive recommendations.

🔖

Cite This Article

ÖZDEMİR, H., BİLGEN, H. S., MEMİŞOĞLU, A., ÜNKAR, Z. A., MUTLU, A., ÖZEK, E. (2019). Do We Have to Obtain Rebound Bilirubin Levels and What is the Optimal Time?. The Journal of Pediatric Research, Cilt: 6 - Sayı: 1, 7–11. https://ajindex.com/articles/362988

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Bhutani VK. Committee on Fetus and Newborn; American Academy of Pediatrics. Phototherapy to prevent severe neonatal hyperbilirubinemia in the newborn infant 35 or more weeks of gestation. Pediatrics 2011;128:1046-52
  2. American Academy of Pediatrics Subcommittee on Hyperbilirubinemia. Management of Hyperbilirubinemia in the Newborn Infant 35 or More Weeks of Gestation. Pediatrics 2004;114:297-316
  3. Yetman RJ, Parks DK, Huseby V, Mistry K, Garcia J. Rebound bilirubin levels in infants receiving phototherapy. J Pediatr 1998;133:705-7
  4. Al-Saedi SA. Rebound hyperbilirubinemia in term infants after phototherapy. Saudi Med J 2002;23:1394-7
  5. Erdeve O, Tiras U, Dallar Y. Rebound bilirubin measurement is not required for hyperbilirubinemia regardless of the background attributes of the newborns. J Trop Pediatr 2004;50:309
  6. Brown AK, Kim MH, Wu PY, Bryla DA. Efficacy of phototherapy in prevention and management of neonatal hyperbilirubinemia. Pediatrics 1985;75:393-400
  7. Maisels MJ, Kring E. Rebound in serum bilirubin level following intensive phototherapy. Arch Pediatr Adolesc Med 2002;156:669-72
  8. Lazar L, Litwin A, Merlob P. Phototherapy for neonatal nonhemolytic hyperbilirubinemia. Analysis of rebound and indications for discontinuing therapy. Clin Pediatr (Phila) 1993;32:264-7
  9. Kaplan M, Kaplan E, Hammerman C, Algur N, Bromiker R, Schimmel MS, et al. Post-phototherapy neonatal bilirubin rebound: a potential cause of significant hyperbilirubinaemia. Arch Dis Child 2006;91:31-4
  10. Bansal A, Jain S, Parmar VR, Chawla D. Bilirubin rebound after intensive phototherapy for neonatal jaundice. Indian Pediatr 2010;47:607-9
  11. Del Vecchio MT, Benstock MA, Sundel ER. Bilirubin rebound. J Pediatr 1999;135:531-2
  12. Linn S, Schoenbaum SC, Monson RR, Rosner B, Stubblefield PG, Ryan KJ. Epidemiology of neonatal hyperbilirubinemia. Pediatrics 1985;75:770-4
  13. Sarici SU, Serdar MA, Korkmaz A, Erdem G, Oran O, Tekinalp G, Yurdakök M, Yigit S. Incidence, course, and prediction of hyperbilirubinemia in near-term and term newborns. Pediatrics 2004;113:775-80
  14. Burke BL, Robbins JM, Bird TM, Hobbs CA, Nesmith C, Tilford JM. Trends in hospitalizations for neonatal jaundice and kernicterus in the United States, 1988-2005. Pediatrics 2009;123:524-32
  15. Olusanya BO, Osibanjo FB, Slusher TM. Risk factors for severe neonatal hyperbilirubinemia in low and middle-income countries: a systematic review and meta-analysis. PLoS One 2015;10:e0117229 16. Committe